Products Technologies Mass Cytometry

Mass Cytometry 

Driving groundbreaking insights at the single-cell level, millions of times 

Mass cytometry, powered by CyTOF® technology, is the world’s most advanced cytometric platform. It has opened new doors to discovery and clinical research by empowering investigators to interrogate more than 50 markers simultaneously on millions of individual cells. Join the hundreds who have reimagined cytometry with CyTOF to unveil new cell types, functions and biomarkers in immunology, cancer, infectious disease and more. 

Workflow

1

Design panel

Easily build panels with up to 50 metal-tagged antibodies and reagents using Maxpar® Panel Designer. Add barcoding to multiplex your samples for even better data quality. Or use pre-built panels to get started! 

2

Prepare samples

CyTOF systems provide highly multiplexed single-cell data from cell suspension samples. Standard protocols for preparing single-cell suspensions from solid or liquid tissues and tumors can be used for CyTOF sample prep. Check out our support page for staining protocols. 

3

Acquire data

The CyTOF XT™ system has fully automated pellet resuspension, calibration bead addition and acquisition of sample batches from the Autosampler carousel.  

The Helios™ system provides the same excellent standard of data quality as CyTOF XT but requires manual resuspension and loading of samples. 

4

Analyze data

CyTOF systems produce standard FCS 3.0 (Helios) or 3.1 (CyTOF XT) data files that can be analyzed with any compatible software, including FCS Express™ and Maxpar Pathsetter™

TRENDING NOW PUBLICATIONS TOPICS

 

Explore these compilations of recent mass cytometry publications focused on specific areas of investigation.

Prevention and treatment of neurological disease

Vaccine development and  efficacy testing

CyTOF for Drug Development

CyTOF for CAR Therapy

Maxpar Direct Immune Profiling Assay

COVID-19 research update

CAR T cells

The value of high-parameter cytometry

Immuno-oncology

Cancer vaccine development

Vaccines for infectious disease

COVID-19 disease research